For small operators trying to understand what federal changes actually mean: This piece breaks down the compliance costs and risks that are often glossed over. Knowledge is power — especially when the stakes are this high.
South Dakota small cannabis operators are being told to relax. Federal rescheduling is here, the story goes, and everything will work out if everyone just stays calm and figures it out as they go.
That is not a serious assessment of what is actually required.
On April 28, 2026, the Department of Justice placed certain FDA-approved marijuana products and marijuana subject to qualifying state medical marijuana licenses into Schedule III of the Controlled Substances Act.¹ State-licensed medical operators who want to operate lawfully under this new federal framework must obtain DEA registration. This is not a paperwork formality.
DEA registration requires applicants to submit detailed security and diversion prevention protocols, comprehensive recordkeeping systems, inventory controls, compliance history disclosures, and facility information that meets federal controlled substance standards.² Operators must also pay registration fees and prepare for inspections and ongoing federal oversight that did not previously exist under South Dakota’s state-only medical program.³
These are not optional best practices. They are mandatory conditions of participating in the federal Schedule III framework.
The financial and operational burden is significant. Industry analyses have already concluded that “the increased DEA compliance costs will partially offset the tax savings achieved by 280E’s nullification. This will increase capital and administrative expenditures, which could put smaller operators at a long-term disadvantage.”⁴ Law firms advising the industry have warned that businesses must now plan for “overlapping federal and state regulatory compliance” and that many legacy facilities were never built to meet federal security, recordkeeping, and manufacturing standards.⁵
For small, independent operators, these requirements create a genuine compliance cliff. Larger, well-capitalized operators with existing professional infrastructure, legal teams, and access to financing are far better positioned to absorb the costs of application preparation, facility upgrades, legal counsel, and ongoing compliance. Smaller operators without those resources face a different reality: they must either find significant new capital or risk operating outside the federal framework that now governs the medical cannabis they are licensed to sell.
This is not theoretical. Even voices outside South Dakota who are generally supportive of rescheduling are being direct about the practical burdens. During the June 3, 2026 Beard Bros webinar “Schedule 3: Harm or Help?,” attorney Amber Lengacher stated that disclosing prior handling of cannabis without a federal license is “super sketch” and that she does not know anyone who is “super comfortable with doing that.”⁶ She further emphasized that “businesses really do need to be consulting with legal counsel… there’s a lot of risk there for sure.”⁷
These are not alarmist statements from critics of rescheduling. They are practical warnings from someone who works with operators navigating the new federal requirements. When even industry counsel is highlighting the disclosure risks, legal complexity, and need for professional guidance, the gap between those warnings and generic local assurances that “we’ll figure it out” becomes difficult to ignore.
The April 28 order established an expedited registration pathway precisely because the federal government recognized that state-licensed operators would need to come into compliance quickly.⁸ That pathway still requires real work, real documentation, and real money. Operators who treat it as something that will simply resolve itself are making a strategic error.
Small operators deserve clear information about what federal Schedule III participation actually demands — not optimistic framing that downplays the capital and operational thresholds now in place. The operators who understand the real costs and requirements earliest will be in the strongest position to make deliberate decisions about their future, whether that means investing in compliance, pursuing consolidation, or pivoting to other work that serves patients.
The federal changes created new pathways. They also created new barriers. Pretending the barriers do not exist does not make them disappear.
Footnotes
¹ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements, 91 Fed. Reg. 22714 (Apr. 28, 2026) (2026-08176).
² Id. at 22719 (detailing registration requirements including security and diversion prevention protocols, recordkeeping, and compliance obligations for state-licensed medical marijuana operators).
³ KVK Lawyers, “The DOJ’s Cannabis Rescheduling Order: Understanding the Next Steps for Operators” (May 1, 2026), https://www.kvklawyers.com/2026/05/01/the-dojs-cannabis-rescheduling-order-understanding-the-next-steps-for-operators/ (noting that applicants must provide state licensing documentation, security and diversion prevention protocols, compliance history disclosures, and that the annual non-refundable application fee is $794).
⁴ Abraham Finberg & Simon Menkes, “Cannabis Rescheduling’s Compliance Costs Will Dent Tax Savings,” Bloomberg Tax, Apr. 28, 2026, https://news.bloombergtax.com/tax-insights-and-commentary/cannabis-reschedulings-compliance-costs-will-dent-tax-savings.
⁵ Foley & Lardner LLP, “Marijuana – Some Products Reclassified to Schedule III: What It Means, What It Doesn’t, and What Comes Next” (Apr. 23, 2026) (discussing the need for substantial capital investment and operational overhauls to meet federal standards).
⁶ Beard Bros Media Network, “Schedule 3: Harm or Help?” (June 3, 2026), https://www.youtube.com/watch?v=gy7dtRNpB4Q (Amber Lengacher discussing disclosure risks for operators who previously handled cannabis without a federal license).
⁷ Id. (Amber Lengacher emphasizing the need for legal counsel and highlighting compliance risks for operators navigating the new federal framework).
⁸ 91 Fed. Reg. at 22719 (establishing expedited registration pathway for qualifying state-licensed medical cannabis entities).
WeedPress: The Paper Trail 
Leave a comment